The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
COLUMN
Bring Your A-Game to Your Next Video Call
With the start we’ve seen to this year, one thing is certain - 2021 is turning out to be a lot more like 2020 than the glory days of 2019. Our new normal is a schedule of Zoom calls, Teams…
To read the full story
COLUMN
- Do You Attract or Repel Winning Candidates?
April 16, 2021
- The Future of Customer Engagement in Japan’s Life Science Industry: One Year Post-COVID
March 19, 2021
- What Personal Biases Influence Your Hires?
February 19, 2021
- Is Your Company Culture Being a Victim of COVID-19?
January 8, 2021
- It’s the Everyday Leaders Your Organization Needs
December 11, 2020
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…